Home › Psychology

📖 13 min read

ADHD in Children: What Evidence Says About Medication and Therapy

What we’re looking at

Attention deficit hyperactivity disorder (ADHD) affects approximately 5% of children worldwide, making it one of the most commonly diagnosed psychiatric conditions in pediatric populations [PMID 28700715]. Children with ADHD typically struggle with inattention, hyperactivity, and impulsivity—symptoms that can significantly impair academic performance, social relationships, and family functioning. The disorder has a strong genetic component, with common genetic variants contributing substantially to susceptibility [PMID 30478444].

Given ADHD’s prevalence and impact, understanding what treatments actually work—and what harms they might cause—is essential for families and clinicians. This review synthesizes evidence from multiple large-scale analyses examining both medication (primarily methylphenidate, the most commonly prescribed stimulant) and non-pharmacological interventions like behavioral therapy. We’ll examine what the research actually shows about effectiveness, how long benefits last, what side effects occur, and where significant gaps in our knowledge remain.

The evidence — what studies actually found

The most comprehensive analysis to date examined 190 randomized trials involving more than 26,000 children and adolescents with ADHD [PMID 28700715]. This network meta-analysis compared 52 different interventions across three broad categories: medications (stimulants like methylphenidate and amphetamine, plus non-stimulants like atomoxetine, guanfacine, and clonidine), psychological interventions (behavioral therapy, cognitive training, and neurofeedback), and complementary/alternative approaches (dietary changes, fatty acids, herbal remedies, and physical activity).

For medication effectiveness, the findings were clear on certain fronts. Methylphenidate and amphetamine demonstrated significantly greater symptom reduction than placebo, and both appeared more effective than atomoxetine and guanfacine [PMID 28700715]. A focused Cochrane review on methylphenidate specifically found that it may improve teacher-rated ADHD symptoms by about 10.6 points on the ADHD Rating Scale (a 0-72 point measure), compared to placebo—exceeding the 6.6-point threshold considered clinically meaningful [PMID 41342306]. This analysis drew from 212 trials involving over 16,000 participants.

Behavioral therapy also showed benefits, particularly when combined with medication. The network analysis found that behavioral therapy combined with stimulants appeared superior to either intervention alone [PMID 28700715]. A separate meta-analysis of cognitive-behavioral therapy (CBT) for externalizing disorders found moderate effects on ADHD symptoms (standardized mean difference of -0.343), with stronger effects on oppositional defiant disorder symptoms, parenting skills, and parental stress [PMID 26575979].

Regarding treatment duration, most medication trials lasted only weeks, not months or years. A meta-analysis specifically examining longer-term methylphenidate studies (12 weeks or more) identified just seven qualifying studies [PMID 25501355]. These showed sustained benefits for both inattention and hyperactivity/impulsivity based on parent and teacher ratings, with effect sizes ranging from 0.96 to 1.25—considered medium to large effects. However, even these “long-term” studies represent only a few months of treatment, not the years many children spend on medication.

How it might work — biological mechanisms

Recent genetic research has begun illuminating ADHD’s biological underpinnings. A genome-wide association study identified 12 independent genetic loci significantly associated with ADHD risk [PMID 30478444]. These genetic variants cluster in evolutionarily constrained genomic regions—areas of DNA that have remained stable across evolutionary time, suggesting they serve critical functions. The associated genes are preferentially expressed in the brain and tend to be intolerant of loss-of-function mutations.

What’s particularly interesting is that genetic risk for ADHD exists on a continuum. The same genetic variants associated with clinical ADHD diagnosis also correlate with ADHD symptom levels in the general population, supporting the idea that clinical ADHD represents the extreme end of continuously distributed traits rather than a categorically distinct condition [PMID 30478444].

Methylphenidate works by blocking the reuptake of dopamine and norepinephrine in the brain, effectively increasing the availability of these neurotransmitters in the synaptic space. These neurotransmitters play crucial roles in attention, impulse control, and executive function—precisely the domains impaired in ADHD. The rapid onset of methylphenidate’s effects (often within an hour) and their quick dissipation when the medication wears off align with this direct neurochemical mechanism.

Behavioral interventions work through different pathways—teaching children specific skills for organization, impulse control, and emotional regulation while helping parents develop more effective behavioral management strategies. These interventions don’t change brain chemistry directly but may strengthen neural circuits involved in self-regulation through repeated practice and reinforcement.

Interestingly, polygenic risk scores for ADHD show associations with numerous other conditions and traits beyond core ADHD symptoms, including anxiety, depression, type 2 diabetes, and respiratory conditions [PMID 36823209]. This suggests shared biological pathways between ADHD and other disorders, though the nature of these connections remains unclear.

Where the evidence is strong (and weak)

The evidence is strongest for short-term efficacy of stimulant medications. Multiple large analyses consistently show that methylphenidate and amphetamine reduce ADHD symptoms more than placebo over periods of weeks to a few months. The effect sizes are moderate to large, and the findings replicate across different countries, settings, and research groups.

However, the certainty of this evidence is surprisingly low. The most recent Cochrane review rated the overall quality of evidence as “very low” [PMID 41342306]. Why? Several critical issues undermine confidence:

First, blinding is severely compromised in medication trials. Methylphenidate causes noticeable side effects—decreased appetite, sleep problems, and others—that are readily apparent to participants, parents, and teachers. When people can guess who’s getting active medication versus placebo (called “unblinding”), it introduces bias into subjective ratings of symptoms and behavior. Of 212 methylphenidate trials reviewed, 191 were rated at high risk of bias, and when considering the unblinding problem, arguably all 212 had high bias risk [PMID 41342306].

Second, we lack good long-term data. While the few studies extending beyond 12 weeks suggest sustained benefits [PMID 25501355], we don’t have rigorous evidence about effects beyond several months, let alone years. Given that many children take these medications throughout childhood and adolescence, this represents a major knowledge gap.

Third, comparative effectiveness between different treatments remains uncertain. While the network meta-analysis suggested that combined behavioral therapy plus stimulants might be superior to either alone [PMID 28700715], these comparisons involve complex statistical modeling across different studies rather than direct head-to-head trials.

For non-medication interventions, the picture is more mixed. The evidence suggests behavioral therapy can help, particularly for improving parenting skills and reducing parental stress [PMID 26575979], but effects on core ADHD symptoms appear smaller than for medication. For cognitive training, neurofeedback, dietary interventions, omega-3 fatty acids, and most complementary approaches, evidence of effectiveness is lacking [PMID 28700715].

Practical takeaways

For families considering ADHD treatment, several practical points emerge from the evidence:

Stimulant medications, particularly methylphenidate, will likely reduce ADHD symptoms noticeably in most children, at least in the short term. The average benefit exceeds what’s considered clinically meaningful, though individual responses vary considerably. Some children show dramatic improvement; others show little benefit or intolerable side effects.

Non-serious side effects are common with methylphenidate. About half of children experience at least one adverse event [PMID 29744873]. The most frequent include difficulty falling asleep (affecting roughly 18% of children), decreased appetite (31%), headache (14%), and abdominal pain (11%). These side effects cause about 6% of children to discontinue medication [PMID 29744873].

Serious adverse events appear rare but cannot be ruled out. The Cochrane review found no clear increased risk of serious adverse events in randomized trials [PMID 41342306], but analysis of non-randomized studies suggested possible increased risks of psychotic symptoms and heart arrhythmias [PMID 29744873]. Because serious adverse events are uncommon, even large studies may miss important risks or fail to identify which children are most vulnerable.

Behavioral interventions offer benefits beyond symptom reduction. Even if effects on core ADHD symptoms are smaller than medication effects, behavioral therapy can improve parenting skills, reduce parental stress and depression, and enhance children’s social competence [PMID 26575979]. These broader family benefits may be particularly valuable for long-term outcomes.

Combination approaches may work best. The available evidence suggests that combining behavioral therapy with medication might be more effective than either alone [PMID 28700715], though more research is needed to confirm this. At minimum, behavioral strategies can help manage symptoms during periods when medication isn’t active (like evenings) or provide tools for situations where medication alone is insufficient.

Limitations of this review

Several limitations deserve emphasis. First, we relied on published systematic reviews and meta-analyses rather than reviewing individual trials ourselves. This approach provides a broad overview but depends on the quality and recency of those source reviews. The most recent comprehensive analysis was published in 2017 [PMID 28700715], though the methylphenidate Cochrane review was updated through 2022 [PMID 41342306].

Second, the underlying evidence quality is “very low” according to GRADE criteria [PMID 41342306], meaning the true effects may differ substantially from what current studies suggest. The pervasive problems with blinding, short study durations, small sample sizes, and publication bias all contribute to this uncertainty.

Third, we focused primarily on symptom reduction as the key outcome. While symptom control is important, families and children may care equally about other outcomes like academic achievement, peer relationships, self-esteem, and quality of life—outcomes less frequently measured or reported in trials. The limited quality-of-life data available suggests methylphenidate may not improve this outcome [PMID 41342306].

Fourth, average effects from meta-analyses don’t tell us which individual children will benefit most or experience the fewest side effects. The genetic research showing ADHD’s polygenic architecture [PMID 30478444] hints at biological heterogeneity that likely translates to treatment response variability, but we cannot yet predict who will respond best to which intervention.

Finally, we didn’t address important questions about optimal dosing, different formulations (immediate-release versus extended-release), treatment breaks, or how to manage the transition from childhood through adolescence to adulthood.

Bottom line

The evidence suggests that both stimulant medications (particularly methylphenidate) and behavioral therapy can reduce ADHD symptoms in children, with medication showing larger short-term effects on core symptoms and behavioral therapy offering broader benefits for family functioning. Combining approaches may be most effective, though research confirming this is limited.

However, the certainty of all this evidence is low. Most medication trials are short, inadequately blinded, and focused narrowly on symptom reduction. We lack good data on long-term effectiveness, optimal treatment duration, which children benefit most, and effects on outcomes beyond symptom checklists.

For families facing ADHD treatment decisions, this means carefully weighing potential benefits against known side effects (which are common, though usually not serious) while recognizing that many questions remain unanswered. Close monitoring, regular reassessment, and willingness to adjust approaches based on individual response are essential, as is consideration of broader family needs beyond just symptom control.

The urgent need for higher-quality, longer-term research highlighted in these reviews [PMID 28700715, PMID 41342306] remains unfulfilled. Future studies should use better methods to maintain blinding, follow children for years rather than weeks, examine which subgroups benefit most from which treatments, and measure outcomes that matter to children and families, not just clinicians.

FAQ: ADHD Treatment in Children

What is the most effective medication for childhood ADHD?

Methylphenidate and amphetamine are the most effective medications for reducing ADHD symptoms in children, showing significantly greater improvement than placebo and non-stimulant medications like atomoxetine and guanfacine [PMID 28700715]. Methylphenidate may improve teacher-rated ADHD symptoms by about 10.6 points on a 72-point scale, exceeding the threshold considered clinically meaningful [PMID 41342306]. However, most evidence comes from short-term studies lasting only weeks, and individual responses to medication vary considerably, so what works best must be determined on a case-by-case basis under medical supervision.

How does behavioral therapy compare to medication for ADHD?

Both behavioral therapy and medication show benefits for childhood ADHD, but they work differently and may address different aspects of the condition. The strongest evidence suggests that combining behavioral therapy with stimulant medication produces superior outcomes compared to either treatment alone [PMID 28700715]. Cognitive-behavioral therapy shows moderate effects on ADHD symptoms themselves (effect size of -0.343) but demonstrates stronger benefits for related problems like oppositional behavior, parenting skills, and parental stress [PMID 26575979]. Behavioral interventions may be particularly valuable for families seeking non-medication approaches or wanting to address the broader family and social impacts of ADHD.

What are the common side effects of ADHD medications in children?

The most commonly reported side effects of methylphenidate include decreased appetite and sleep problems, which appear more frequently than with placebo treatment [PMID 41342306]. However, the comprehensive analysis of 190 trials found that evidence on adverse events was generally of very low quality, making it difficult to fully characterize the safety profile [PMID 28700715]. Most medication trials lasted only weeks, not months or years, creating uncertainty about long-term side effects. This limitation in safety data represents a significant gap in our understanding, particularly for medications children may take for extended periods during critical developmental years.

How long do ADHD treatments need to continue to be effective?

This remains one of the most significant unanswered questions in ADHD treatment. Most medication trials lasted only weeks, creating substantial uncertainty about whether benefits persist with long-term use or what happens when treatment stops [PMID 28700715, 41342306]. The short duration of most studies means we have limited evidence about whether children need continuous treatment, whether benefits are maintained after discontinuation, or how treatment needs might change as children develop. This gap in long-term evidence makes it challenging for families and clinicians to make fully informed decisions about sustained treatment strategies.

Why is ADHD so common, and does genetics play a role?

ADHD affects approximately 5% of children worldwide, making it one of the most commonly diagnosed psychiatric conditions in pediatric populations [PMID 28700715]. The disorder has a strong genetic component, with common genetic variants contributing substantially to susceptibility [PMID 30478444]. This genetic basis helps explain why ADHD often runs in families, though environmental factors also play important roles. The high prevalence reflects both genuine biological variation in attention and impulse control systems and the significant impairment these differences can cause in modern educational and social environments that demand sustained attention and behavioral regulation.

Studies referenced

  • PMID 28700715 — Network meta-analysis of 190 randomized trials comparing pharmacological, psychological, and complementary interventions for ADHD in children and adolescents, finding stimulants and behavioral therapy most effective.

  • PMID 30478444 — Genome-wide association study identifying 12 genetic loci significantly associated with ADHD and demonstrating that clinical ADHD represents the extreme of continuously distributed heritable traits.

  • PMID 26575979 — Meta-analysis of cognitive-behavioral therapy for externalizing disorders showing moderate effects on ADHD symptoms and larger effects on parenting skills and parental stress.

  • PMID 41342306 — Updated Cochrane systematic review of methylphenidate for childhood ADHD covering 212 trials, rating evidence quality as very low despite finding probable benefits for symptom reduction.

  • PMID 36823209 — Phenome-wide association study using polygenic risk scores showing genetic associations between Tourette syndrome and multiple other conditions including ADHD, revealing shared genetic architecture.

  • PMID 39667386 — Global analysis of progress toward nutrition targets from the Global Burden of Disease Study, examining child health indicators including low birthweight and growth outcomes across 204 countries.

  • PMID 29744873 — Systematic review of adverse events from methylphenidate in non-randomized studies, finding common non-serious side effects and possible associations with rare serious events.

  • PMID 25501355 — Meta-analysis of seven long-term studies (12+ weeks) of methylphenidate immediate-release showing sustained efficacy for ADHD symptoms in children.


Source

  • PMID: 28700715 (read full paper on PubMed)
  • Journal: PloS one (2017)

Articles on this site are adapted from PubMed abstracts as general-interest explainers. They are not intended as medical advice.

📝 This article was adapted by the PubMed Trivia editorial team using Claude (Anthropic) as an adaptation assistant, based on the PubMed abstract cited above. Our editorial workflow includes automated NG-term checks (medical-claims law), careful "correlation vs causation" distinction, and mandatory PMID + source URL disclosure. See the full pipeline on our editorial policy and editor pages. Please report errors to sciencepubmedjp@gmail.com (we respond within 48 hours).